Randomized trial of 8-week versus 12-week VNCOP-B plus G-CSF regimens as front-line treatment in elderly aggressive non-Hodgkin's lymphoma patients

Annals of Oncology

Volumn 13, Issue 9, 2002, Pages 1364-1369

  Zinzani, P L ^a   Gherlinzoni, F ^a   Storti, S ^b   Zaccaria, A ^c   Pavone, E ^d   Moretti, L ^e   Gentilini, P ^f   Guardigni, L ^g   De Renzo, A ^h   Fattori, P P ⁱ   Falini, B ^j   Lauta, V M ^k   Mannina, D ^l   Zaja, F ^c   Mazza, P ^m   Volpe, E ⁿ   Lauria, F ^o   Aitini, E ^p   Ciccone, F ^q   Tani, M ^a   Stefoni, V ^a   Alinari, L ^a   Baccarani, M ^a   Tura, S ^a   more..

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIVERSITY OF PERUGIA   (Italy)

^c UNIVERSITY OF BARI   (Italy)

^d Messina Hospital   (Italy)

^e UNIVERSITY OF UDINE   (Italy)

^f Hospital of Taranto   (Italy)

^g ASL Avellino 'A Landolfi Hospital'   (Italy)

^h UNIVERSITY OF SIENA   (Italy)

ⁱ Mantova Hospital   (Italy)

^j Latina Hospital   (Italy)

^k CATHOLIC UNIVERSITY   (Italy)

^l Ravenna Hospital   (Italy)

^m SAN SALVATORE HOSPITAL   (Italy)

ⁿ Oncology Division   (Italy)

^o Cesena Hospital   (Italy)

^p UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^q Internal Medicine and Rheumatology Rimini Hospital   (Italy)

more..

Author keywords

Aggressive non Hogdkin's lymphoma; Elderly patients; Granulocyte colony stimulating factor; VNCOP B regimen

Indexed keywords

BLEOMYCIN; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; METHOTREXATE; MITOXANTRONE; PREDNISONE; VINCRISTINE;

ADULT; AGED; ARTICLE; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CANCER REGRESSION; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; FEMALE; GERIATRIC PATIENT; HUMAN; INFECTION COMPLICATION; ITALY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEUTROPENIA; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SURVIVAL RATE; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 0036739094     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/mdf208     Document Type: Article

References (38)

1. Devesa SS, Fears T. Non-Hodgkin's lymphoma time trends: United States and international data. Cancer Res 1992; 52: 5432-5440.
2. Morgan G, Vornanen M, Puitinen J et al. Changing trends in the incidence of non-Hodgkin's lymphoma in Europe. Biomed Study Group. Ann Oncol 1997; 8 (Suppl 2): 49-54.
3. National Cancer Institute. Cancer Statistics Review, 1973-1988; NIH publication 91-2789. Bethesda: National Cancer Institute 1991.
4. Jones SE, Fuks Z, Bull M et al. Non-Hodgkin's lymphomas: IV. Clinicopathologic correlation in 405 cases. Cancer 1973; 31: 806-823.
5. Nathwani BN, Kim H, Rappaport H et al. Non-Hodgkin's lymphomas: a clinicopathologic study comparing two classifications. Cancer 1978; 41: 303-325.
6. Anderson T, Chabner BA, Young RC et al. Malignant lymphoma: I. The histology and staging of 473 patients at the National Cancer Institute. Cancer 1982; 50: 2708-2721.
7. Bessel EM, Coutts A, Fletcher J et al. Non-Hodgkin's lymphoma in elderly patients: a phase II study of MCOP chemotherapy in patients aged 70 years or over with intermediate or high-grade histology. Eur J Cancer 1994; 30A: 1337-1442.
8. Armitage JO, Potter JF. Aggressive chemotherapy for diffuse histiocytic lymphoma in the elderly. Increased complications with advancing age. J Am Geriatr Soc 1984; 32: 269-273.
9. Novitzky N, King HS, Johnson C, Jacobs P. Treatment of aggressive non-Hodgkin's lymphoma in the elderly. Am J Hematol 1995; 49: 103-107.
10. Tirelli U, Zagonel V, Errante D et al. A prospective study of a new combination chemotherapy regimen in patients older than 70 years with unfavorable non-Hodgkin's lymphoma. J Clin Oncol 1992; 10: 228-236.
11. Salvagno L, Contu A, Bianco A. A combination of mitoxantrone, etoposide and prednisone in elderly patients with non-Hodgkin's lymphoma. Ann Oncol 1992; 3: 833-837.
12. O'Reilly SE, Connors JM, Howdle S et al. In search of an optimal regimen for elderly patients with advanced-stage diffuse large-cell lymphoma. J Clin Oncol 1993; 11: 2250-2257.
13. Ansell SM. A phase II trial of chemotherapy combination in elderly patients with aggressive lymphoma. Ann Oncol 1993; 4: 172.
14. Tirelli U, Carbone A, Zagonel V et al. Non-Hodgkin's lymphoma in the elderly: prospective studies with specifically devised chemotherapy regimens in 66 patients. Eur J Cancer Clin Oncol 1987; 23: 535-540.
15. McMaster ML, Johnson DH, Greer JP et al. A brief-duration combination chemotherapy for elderly patients with poor-prognosis non-Hodgkin's lymphoma. Cancer 1991; 67: 1487-1492.
16. Martelli M, Guglielmi C, Coluzzi S et al. P-VABEC: a prospective study of a new weekly chemotherapy regimen for elderly aggressive non-Hodgkin's lymphoma. J Clin Oncol 1993; 11: 2362-2369.
17. Bastion Y, Blay JY, Divine M et al. Elderly patients with aggressive non-Hodgkin's lymphoma: disease presentation, response to treatment, and survival - a Groupe d'Etude des Lymphomes de l'Adulte Study on 453 patients older than 69 years. J Clin Oncol 1997; 15: 2945-2953.
18. Bertini M, Freilone R, Vitolo U et al. P-VEBEC: a new 8-weekly schedule with or without rG-CSF for elderly patients with aggressive non-Hodgkin's lymphoma (NHL). Ann Oncol 1994; 5: 895-900.
19. Meyer RM, Browman GP, Samosh ML et al. Randomized phase II comparison of standard CHOP with weekly CHOP in elderly patients with non-Hodgkin's lymphoma. J Clin Oncol 1995; 13: 2386-2393.
20. Sonneveld P, de Ridder M, van der Lelie H et al. Comparison of doxorubicin and mitoxantrone in the treatment of elderly patients with advanced diffuse non-Hodgkin's lymphoma using CHOP versus CNOP chemotherapy. J Clin Oncol 1995; 13: 2530-2539.
21. Tirelli U, Errante D, Van Glabbeke M et al. CHOP is the standard regimen in patients ≥70 years of age with intermediate-grade and high-grade non-Hodgkin's lymphoma: results of a randomized study of the European Organization for Research and Treatment of Cancer Lymphoma Cooperative Study Group. J Clin Oncol 1998; 16: 27-34.
22. Zinzani PL, Bendandi M, Gherlinzoni F et al. VNCOP-B regimen in the treatment of high-grade non-Hodgkin's lymphoma in the elderly. Haematologica 1993; 78: 378-382.
23. Zinzani PL, Pavone E, Storti S et al. Randomized trial with or without granulocyte colony-stimulating factor as adjunct to induction VNCOP-B treatment of elderly high-grade non-Hodgkin's lymphoma. Blood 1997; 89: 3974-3979.
24. Zinzani PL, Storti S, Zaccaria A et al. Elderly aggressive-histology non-Hodgkin's lymphoma: first-line VNCOP-B regimen experience on 350 patients. Blood 1999; 94: 33-38.
25. Harris N, Jaffe E, Stein H et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 1994; 84: 1361-1392.
26. Carbone PP, Kaplan HS, Musshoff K. Report of the Committee on Hodgkin's Disease Staging Classifications. Cancer Res 1971; 31: 1860-1861.
27. Oken M, Creech R, Tormey D. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982; 5: 649-655.
28. A predictive model for aggressive non-Hodgkin's lymphoma. International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 1993; 329: 987-994.
29. Klimo P, Connors JM, MACOP-B chemotherapy for the treatment of diffuse large-cell lymphoma. Ann Intern Med 1985; 102: 596-602.
30. Kaplan EL, Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-462.
31. Cox DR. Regression models and life tables (with discussion). J R Stat Soc B 1972; 34: 187-190.
32. Vose JM, Armitage JO, Weisenburger DD et al. The importance of age in survival of patients treated with chemotherapy for aggressive non-Hodgkin's lymphoma. J Clin Oncol 1988; 6: 1838-1844.
33. Dixon DO, Neilan B, Jones S et al. Effect of age on therapeutic outcome in advanced diffuse histocytic lymphoma: the Southwest Oncology Group experience. J Clin Oncol 1986; 4: 295-305.
34. Greil R. Prognosis and management strategies of lymphatic neoplasias in the elderly. Oncology 1998; 55: 265-275.
35. Fisher RI, Gaynor ER, Dhalberg S et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 1993; 328: 1002-1006.
36. Mainwaring PN, Cunningham D, Gregory W et al. Mitoxantrone is superior to doxorubicin in a multiagent weekly regimen for patients older than 60 with high-grade lymphoma: results of a BNLI randomized trial of PAdriaCEBO versus PMitCEBO. Blood 2001; 97: 2991-2997.
37. Zinzani PL, Tani M, Stefoni V et al. Efficacy of vinorelbine, epirubicin and prednisone combination regimen in pretreated elderly patients with aggressive non-Hodgkin's lymphoma. Haematologica 2001; 86: 287-290.
38. Coiffier B, Lepage E, Gaulard P et al. Prognostic factors affecting the efficacy of rituximab plus CHOP (R-CHOP) therapy in elderly patients with diffuse large B-cell lymphoma (DLCL): results of a randomized GELA trial. Proc Am Soc Clin Oncol 2001; 20: 1131-1139.